These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28043759)

  • 1. Baseline plasma chromogranin A levels in patients with well-differentiated neuroendocrine tumors of the pancreas: A potential predictor of postoperative recurrence.
    Nanno Y; Toyama H; Matsumoto I; Otani K; Asari S; Goto T; Ajiki T; Zen Y; Fukumoto T; Ku Y
    Pancreatology; 2017; 17(2):291-294. PubMed ID: 28043759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden.
    Jilesen AP; Busch OR; van Gulik TM; Gouma DJ; Nieveen van Dijkum EJ
    Dig Surg; 2014; 31(6):407-14. PubMed ID: 25572908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors.
    Genç CG; Jilesen APJ; Nieveen van Dijkum EJM; Klümpen HJ; van Eijck CHJ; Drozdov I; Malczewska A; Kidd M; Modlin I
    J Surg Oncol; 2018 Jul; 118(1):37-48. PubMed ID: 30114319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
    Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
    J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
    Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
    Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
    Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
    Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
    J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
    Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
    Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
    J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm.
    Paik WH; Ryu JK; Song BJ; Kim J; Park JK; Kim YT; Yoon YB
    J Korean Med Sci; 2013 May; 28(5):750-4. PubMed ID: 23678268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
    Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
    Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?
    Walter T; Chardon L; Chopin-laly X; Raverot V; Caffin AG; Chayvialle JA; Scoazec JY; Lombard-Bohas C
    Eur J Cancer; 2012 Aug; 48(12):1766-73. PubMed ID: 22133573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Elastase 1 Level as a Risk Factor for Postoperative Recurrence in Patients with Well-Differentiated Pancreatic Neuroendocrine Neoplasms.
    Nanno Y; Toyama H; Zen Y; Akita M; Ando Y; Mizumoto T; Ueda Y; Ajiki T; Okano K; Suzuki Y; Fukumoto T
    Ann Surg Oncol; 2018 Oct; 25(11):3358-3364. PubMed ID: 30054822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
    Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
    Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
    Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
    Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.
    Corsello A; Di Filippo L; Massironi S; Sileo F; Dolcetta Capuzzo A; Gemma M; Carlucci C; Cusini C; Colombo B; Dallatomasina A; Franchi GM; Corti A; Manzoni MF
    PLoS One; 2018; 13(5):e0196858. PubMed ID: 29723285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.
    Tian T; Gao J; Li N; Li Y; Lu M; Li Z; Lu Z; Li J; Shen L
    PLoS One; 2016; 11(5):e0154679. PubMed ID: 27159453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
    Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
    Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
    Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
    BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.